Pfizer, 23andMe team up to study bowel disease

Pfizer Inc. is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.

Under the partnership, 23andMe will map the DNA of 10,000 patients who have forms of the disease, which include Crohn's disease and ulcerative colitis. Patients will submit saliva samples using 23andMe's at-home collection kit and then fill out online questionnaires about their disease and symptoms.

The companies say they hope to identify genetic similarities among patients with , which could guide development of targeted drugs to treat the disease.

The cause of is unknown, though many scientists suspect genetics play a role. Other scientists believe the diseases are triggered by a virus or bacteria.

Related Stories

Inflammatory bowel disease raises risk of melanoma

date May 20, 2013

Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...

Recommended for you

A high-fat diet may alleviate mitochondrial disease

date Jun 30, 2015

Mice that have a genetic version of mitochondrial disease can easily be mistaken for much older animals by the time they are nine months old: they have thinning grey hair, osteoporosis, poor hearing, infertility, ...

Cheek muscles hold up better than leg muscles in space

date Jun 30, 2015

It is well known that muscles need resistance (gravity) to maintain optimal health, and when they do not have this resistance, they deteriorate. A new report published in the July 2015 issue of The FASEB Journal, however, sugges ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.